Table 3.
Scenario | N | Incremental costs, £ (95% CI) | Incremental QALYs (95% CI) | Net monetary benefit, £* |
Primary analysis, adjusted† | 274 | −5095.92 (−8736.33 to −1455.51) |
0.0034 (−0.0712 to 0.0780) |
5163.98 |
Primary analysis, unadjusted‡ | 274 | −5539.10 (−9483.26 to −1594.95) |
−0.0005 (−0.0723 to 0.0714) |
5530.04 |
Scenario I: | ||||
Complete case analysis, adjusted† | 89 | −1609.85 (−7036.27 to 3816.57) |
−0.0239 (−0.0605 to 0.0127) |
1131.62 |
Complete case analysis, unadjusted‡ | 94 | −2752.84 (−8438.59 to 2932.91) |
−0.0157 (−0.0536 to 0.0221) |
3570.69 |
Scenario II: | ||||
Incl. NYHA class I patients, adjusted† | 295 | −4572.69 (−8030.66 to −1114.73) |
−0.0037(-0.0736 to 0.0663) | 4498.88 |
Incl. NYHA class I patients, unadjusted‡ | 295 | −4857.43 (−8587.98 to −1126.88) |
−0.0061 (-0.0730 to 0.0609) | 4736.20 |
Scenario III: | ||||
Excl. top 10th percentile resource-heavy patients, leaving out municipality costs, adjusted† | 247 | −3060.50 (−4836.08 to −1284.93) |
−0.0096 (-0.0949 to 0.0756) | 2867.62 |
Excl. top 10th percentile resource-heavy patients, leaving out municipality costs, unadjusted‡ | 247 | −3181.34 (−5103.28 to −1259.40) |
−0.0130 (-0.0944 to 0.0683) | 2921.12 |
*Estimated based on an expected cost-effectiveness threshold of £20 000 per QALY.
†Seemingly unrelated regression, adjustment for group allocation, age, gender, baseline EQ-5D-3L summary score, total costs in the year preceding the study start date, self-reported NYHA classification at baseline, the self-reported length of HF diagnosis, education level, relationship status and the presence of self-reported smoking, diabetes mellitus, psychological disorder, COPD, cancer and musculoskeletal disorder.
‡Seemingly unrelated regression with intervention group as the only predictor.
£, British Pounds Sterling; COPD, chronic obstructive pulmonary disease; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels; Excl., excluding; HF, heart failure; Incl., including; NYHA, New York Heart Association; QALYs, Quality-adjusted life-years.